Sonoma Pharmaceuticals (SNOA) director granted 10,000 stock options at $3.68

Rhea-AI Filing Summary

Sonoma Pharmaceuticals director granted new stock options

A director of Sonoma Pharmaceuticals, Inc. received a stock option grant covering 10,000 shares of common stock on 01/02/2026 at an exercise price of $3.68 per share. These options vest in three equal parts on 01/02/2027, 01/02/2028, and 01/02/2029, or earlier upon a change of control, and expire on 01/02/2036. After this grant, the director beneficially owns 20,001 derivative securities, held directly, as compensation for Board service under the company’s annual stock option program.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weigerstorfer Philippe

(Last) (First) (Middle)

C/O SONOMA PHARMACEUTICALS, INC.

5445 CONESTOGA COURT, SUITE 150

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sonoma Pharmaceuticals, Inc. [ SNOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$3.68	01/02/2026		A		10,000		(1)	01/02/2036	Common Stock	10,000	(2)	20,001	D

Explanation of Responses:

1. The options vest one third each on 1/2/2027, 1/2/2028 and 1/2/2029, or upon change of control.

2. The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors as part of the Company's annual grant of stock options.

	/s/ Amy Trombly as attorney-in-fact	01/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sonoma Pharmaceuticals (SNOA) report on this Form 4?

The filing reports that a director of Sonoma Pharmaceuticals, Inc. (SNOA) received a grant of stock options to purchase 10,000 shares of common stock on 01/02/2026 at an exercise price of $3.68 per share.

What are the vesting terms of the new Sonoma Pharmaceuticals (SNOA) stock options?

The options vest in three equal installments, one third each on 01/02/2027, 01/02/2028, and 01/02/2029, or upon a change of control of the company.

When do the newly granted Sonoma Pharmaceuticals (SNOA) options expire?

The reported stock options expire on 01/02/2036, giving the director a long-term window to exercise the right to purchase 10,000 shares.

How many derivative securities does the Sonoma Pharmaceuticals (SNOA) director own after this grant?

Following the reported transaction, the director beneficially owns 20,001 derivative securities related to Sonoma Pharmaceuticals common stock, held in direct ownership form.

Why were these Sonoma Pharmaceuticals (SNOA) options granted to the director?

The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors as part of the company’s annual grant of stock options.

What type of security is involved in this Sonoma Pharmaceuticals (SNOA) Form 4 filing?

The filing involves a stock option (right to buy), a derivative security that allows the director to purchase Sonoma Pharmaceuticals common stock at a fixed exercise price.